Record free cash flow of approximately $700 million and achieved net cash position Increased 2025 share buyback target by 20% to $600 million and ...
NeoGenomics’ third quarter results were met with a negative market reaction, as shares declined following the announcement. Management attributed the quarter’s performance to robust growth in clinical ...
Veracyte, Inc. , a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research tool's ...
The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...
Q3 2025 Management View CEO Jacob Thaysen reported, "In the third quarter, we delivered another strong performance with ...
Switzerland launches a major AI project to advance precision oncology and bring artificial intelligence into cancer diagnosis and treatment.
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2025 following ...
“These results are encouraging, highlighting TET2-mutated clonal hematopoiesis as a potential biomarker to select patients ...
Twist Bioscience is advancing synthetic DNA manufacturing with innovation but remains at the lower end of its 52-week range.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback